PharmaCyte Biotech PMCB
NASDAQ PMCB
$0.39 -0.01 (-1.63%)
As of: Nov 12, 2026 · 10:14 AM EST

PharmaCyte Biotech (PMCB) Net Income Attributable to Noncontrolling Interests (2023 - 2025)

Updated

PharmaCyte Biotech (PMCB) posted Income from Non-Controlling Interests of -$3.05 million for fiscal Q3 2025 (quarter ended Jan 31, 2025), compared with -$5.62 million a year earlier.

Analysis

PharmaCyte Biotech (PMCB) Net Income Attributable to Noncontrolling Interests (2023 - 2025) Analysis & Trends

For the trailing twelve months through Jan 31, 2025, Income from Non-Controlling Interests at PharmaCyte Biotech was -$13.88 million.

  • Quarterly Income from Non-Controlling Interests has run from a low of -$5.62 million in fiscal Q3 2024 to a high of -$2.26 million in fiscal Q2 2024 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 PharmaCyte Biotech 4.29 Mn -68.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2025 -3.05 Mn
Oct 31, 2024 -2.96 Mn
Jan 31, 2024 -5.62 Mn
Oct 31, 2023 -2.26 Mn
API Access

PharmaCyte Biotech Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=PMCB&period=max&api_key=YOUR_API_KEY